Perils, problems, and progress in laboratory diagnosis of Von Willebrand disease

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 1, 2014, Pages 41-48

  Flood, Veronica H ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

bleeding; collagen; platelets; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN TYPE 6; RISTOCETIN; RISTOCETIN COFACTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AGAR GEL ELECTROPHORESIS; ARTICLE; BLOOD CLOTTING; CHROMOGENIC FACTOR XIII ASSAY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; LABORATORY TEST; LATEX IMMUNOASSAY; PATIENT CARE; PRIORITY JOURNAL; PROTEIN BINDING; SURVIVAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; VALVULAR HEART DISEASE; VON WILLEBRAND DISEASE;

CLINICAL LABORATORY TECHNIQUES; HUMANS; VON WILLEBRAND DISEASES;

EID: 84893041204     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1363166     Document Type: Article

References (80)

1. Weiss H. J., Sussman I. I., Hoyer L. W. Stabilization of factor VIII in plasma by the Von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with Von Willebrand's disease. J Clin Invest: 1977; 60 2 390 404 (Pubitemid 8154146)
2. Mohri H., Fujimura Y., Shima M., et al. Structure of the Von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem: 1988; 263 34 17901 17904 (Pubitemid 19005061)
3. Pareti F. I., Niiya K., McPherson J. M., Ruggeri Z. M. Isolation and characterization of two domains of human Von Willebrand factor that interact with fibrillar collagen types I and III. J Biol Chem: 1987; 262 28 13835 13841 (Pubitemid 17144318)
4. Sadler J. E., Budde U., Eikenboom J. C., et al. Working Party on Von Willebrand Disease Classification. Update on the pathophysiology and classification of Von Willebrand disease: a report of the Subcommittee on Von Willebrand Factor. J Thromb Haemost: 2006; 4 10 2103 2114 (Pubitemid 44403432)
5. Goodeve A. C. The genetic basis of Von Willebrand disease. Blood Rev: 2010; 24 3 123 134
6. Zimmerman T. S., Dent J. A., Ruggeri Z. M., Nannini L. H. Subunit composition of plasma Von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB Von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest: 1986; 77 3 947 951 (Pubitemid 16067969)
7. Ruggeri Z. M., Lombardi R., Gatti L., Bader R., Valsecchi C., Zimmerman T. S. Type IIB Von Willebrand's disease: differential clearance of endogenous versus transfused large multimer von willebrand factor. Blood: 1982; 60 6 1453 1456 (Pubitemid 13211388)
8. Mancuso D. J., Kroner P. A., Christopherson P. A., Vokac E. A., Gill J. C., Montgomery R. R. Type 2M:Milwaukee-1 Von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the Von Willebrand factor A1 domain causes deficient binding of Von Willebrand factor to platelets. Blood: 1996; 88 7 2559 2568 (Pubitemid 26327506)
9. Mazurier C., Dieval J., Jorieux S., Delobel J., Goudemand M. A new Von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood: 1990; 75 1 20 26 (Pubitemid 20031484)
10. Favaloro E. J. Diagnosis and classification of Von Willebrand disease: a review of the differential utility of various functional Von Willebrand factor assays. Blood Coagul Fibrinolysis: 2011; 22 7 553 564
11. Ingerslev J. A sensitive ELISA for Von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest: 1987; 47 2 143 149 (Pubitemid 17050196)
12. Castaman G., Tosetto A., Cappelletti A., et al. Validation of a rapid test (VWF-LIA) for the quantitative determination of Von Willebrand factor antigen in type 1 Von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res: 2010; 126 3 227 231
13. Kempfer A. C., Silaf M. R., Farias C. E., Carballo G. A., Woods A. I., Lazzari M. A. Binding of Von Willebrand factor to collagen by flow cytometry. Am J Clin Pathol: 1999; 111 3 418 423 (Pubitemid 29102752)
14. Mina A., Favaloro E. J., Koutts J. A novel flow cytometry single tube bead assay for quantitation of Von Willebrand factor antigen and collagen-binding. Thromb Haemost: 2012; 108 5 999 1005
15. Gill J. C., Endres-Brooks J., Bauer P. J., Marks W. J. Jr, Montgomery R. R. The effect of ABO blood group on the diagnosis of Von Willebrand disease. Blood: 1987; 69 6 1691 1695 (Pubitemid 17091627)
16. Miller C. H., Haff E., Platt S. J., et al. Measurement of Von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost: 2003; 1 10 2191 2197
17. Hellgren M., Blombäck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest: 1981; 12 3 141 154 (Pubitemid 11150978)
18. Stakiw J., Bowman M., Hegadorn C., et al. The effect of exercise on Von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B Von Willebrand disease. J Thromb Haemost: 2008; 6 1 90 96
19. Sadler J. E. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood: 2003; 101 6 2089 2093 (Pubitemid 36302041)
20. Howard M. A., Sawers R. J., Firkin B. G. Ristocetin: a means of differentiating Von Willebrand's disease into two groups. Blood: 1973; 41 5 687 690
21. Sakariassen K. S., Bolhuis P. A., Sixma J. J. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature: 1979; 279 5714 636 638 (Pubitemid 9198858)
22. Federici A. B., Canciani M. T., Forza I., Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 Von Willebrand disease-single center comparison of four different assays. Thromb Haemost: 2000; 84 6 1127 1128 (Pubitemid 32014059)
23. Favaloro E. J., Lillicrap D., Lazzari M. A., et al. Von Willebrand disease: laboratory aspects of diagnosis and treatment. Haemophilia: 2004; 10 04 164 168 (Pubitemid 40045437)
24. Nichols W. L., Hultin M. B., James A. H., et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia: 2008; 14 2 171 232 (Pubitemid 351343618)
25. Kitchen S., Jennings I., Woods T. A., Kitchen D. P., Walker I. D., Preston F. E. Laboratory tests for measurement of Von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost: 2006; 32 5 492 498 (Pubitemid 44157387)
26. Meijer P., Haverkate F. An external quality assessment program for Von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost: 2006; 32 5 485 491 (Pubitemid 44157386)
27. Flood V. H., Gill J. C., Morateck P. A., et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood: 2010; 116 2 280 286
28. Flood V. H., Friedman K. D., Gill J. C., et al. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood: 2013; 121 18 3742 3744
29. Murdock P. J., Woodhams B. J., Matthews K. B., Pasi K. J., Goodall A. H. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost: 1997; 78 4 1272 1277 (Pubitemid 27464598)
30. Hulstein J. J., de Groot P. G., Silence K., Veyradier A., Fijnheer R., Lenting P. J. A novel nanobody that detects the gain-of-function phenotype of Von Willebrand factor in ADAMTS13 deficiency and Von Willebrand disease type 2B. Blood: 2005; 106 9 3035 3042 (Pubitemid 41565896)
31. Vanhoorelbeke K., Cauwenberghs N., Vauterin S., Schlammadinger A., Mazurier C., Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of Von Willebrand factor. Thromb Haemost: 2000; 83 1 107 113 (Pubitemid 30045485)
32. Federici A. B., Canciani M. T., Forza I., et al. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low Von Willebrand factor levels. Haematologica: 2004; 89 1 77 85 (Pubitemid 38165858)
33. Patzke J., Schneppenheim R. Laboratory diagnosis of Von Willebrand disease. Hamostaseologie: 2010; 30 4 203 206
34. Flood V. H., Gill J. C., Morateck P. A., et al. Gain-of-function GPIb ELISA assay for VWF activity in the zimmerman program for the molecular and clinical biology of VWD. Blood: 2011; 117 6 e67 e74
35. Chen D., Daigh C. A., Hendricksen J. I., et al. A highly-sensitive plasma Von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost: 2008; 6 2 323 330
36. Chen D., Tange J. I., Meyers B. J., Pruthi R. K., Nichols W. L., Heit J. A. Validation of an automated latex particle-enhanced immunoturbidimetric Von Willebrand factor activity assay. J Thromb Haemost: 2011; 9 10 1993 2002
37. Langdell R. D., Wagner R. H., Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med: 1953; 41 4 637 647
38. Verbruggen B., Meijer P., Novákova I., Van Heerde W. Diagnosis of factor VIII deficiency. Haemophilia: 2008; 14 03 76 82 (Pubitemid 351722387)
39. Mazurier C., Meyer D. Factor VIII binding assay of Von Willebrand factor and the diagnosis of type 2N Von Willebrand disease-results of an international survey. On behalf of the Subcommittee on Von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost: 1996; 76 2 270 274 (Pubitemid 26285264)
40. Federici A. B. Diagnosis of inherited Von Willebrand disease: a clinical perspective. Semin Thromb Hemost: 2006; 32 6 555 565 (Pubitemid 44453017)
41. Ruggeri Z. M., Zimmerman T. S. Variant Von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/Von Willebrand factor in plasma and platelets. J Clin Invest: 1980; 65 6 1318 1325 (Pubitemid 10122373)
42. Budde U., Pieconka A., Will K., Schneppenheim R. Laboratory testing for Von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost: 2006; 32 5 514 521 (Pubitemid 44157390)
43. Budde U., Schneppenheim R., Eikenboom J., et al. Detailed Von Willebrand factor multimer analysis in patients with Von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 Von Willebrand disease (MCMDM-1VWD). J Thromb Haemost: 2008; 6 5 762 771 (Pubitemid 351524536)
44. Heyde E. Gastrointestinal bleeding in aortic stenosis. N Engl J Med: 1958; 259 196
45. Gill J. C., Wilson A. D., Endres-Brooks J., Montgomery R. R. Loss of the largest Von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood: 1986; 67 3 758 761 (Pubitemid 16130269)
46. Favaloro E. J., Facey D., Grispo L. Laboratory assessment of Von Willebrand factor. Use of different assays can influence the diagnosis of Von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms. Am J Clin Pathol: 1995; 104 3 264 271
47. Flood V. H., Gill J. C., Friedman K. D., et al. Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant Von Willebrand disease. Clin Chem: 2013; 59 4 684 691
48. Nyman D. Interaction of collagen with the factor VIII antigen-activity - Von Willebrand factor complex. Thromb Res: 1977; 11 3 433 438 (Pubitemid 8197181)
49. Hoylaerts M. F., Yamamoto H., Nuyts K., Vreys I., Deckmyn H., Vermylen J. Von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem J: 1997; 324 Pt 1 185 191 (Pubitemid 27229381)
50. Ribba A. S., Loisel I., Lavergne J. M., et al. Ser968Thr mutation within the A3 domain of Von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost: 2001; 86 3 848 854 (Pubitemid 32834196)
51. Riddell A. F., Gomez K., Millar C. M., et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of Von Willebrand factor. Blood: 2009; 114 16 3489 3496
52. Flood V. H., Lederman C. A., Wren J. S., et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost: 2010; 8 6 1431 1433
53. Brown J. E., Bosak J. O. An ELISA test for the binding of Von Willebrand antigen to collagen. Thromb Res: 1986; 43 3 303 311 (Pubitemid 16060834)
54. Favaloro E. J. Collagen binding assay for Von Willebrand factor (VWF:CBA): detection of Von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost: 2000; 83 1 127 135 (Pubitemid 30045488)
55. Favaloro E. J. Evaluation of commercial Von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 Von Willebrand disease. Thromb Haemost: 2010; 104 5 1009 1021
56. Favaloro E. J. An update on the Von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost: 2007; 33 8 727 744 (Pubitemid 351158442)
57. Favaloro E. J. Toward a new paradigm for the identification and functional characterization of Von Willebrand disease. Semin Thromb Hemost: 2009; 35 1 60 75
58. Adcock D. M., Bethel M., Valcour A. Diagnosing Von Willebrand disease: a large reference laboratory's perspective. Semin Thromb Hemost: 2006; 32 5 472 479 (Pubitemid 44157384)
59. Flood V. H., Gill J. C., Christopherson P. A., et al. Comparison of type I, type III and type VI collagen binding assays in diagnosis of Von Willebrand disease. J Thromb Haemost: 2012; 10 7 1425 1432
60. Flood V. H., Gill J. C., Christopherson P. A., et al. Critical Von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost: 2012; 10 7 1417 1424
61. Larsen D. M., Haberichter S. L., Gill J. C., Shapiro A. D., Flood V. H. Variability in platelet- and collagen-binding defects in type 2M Von Willebrand disease. Haemophilia: 2013; 19 4 590 594
62. Haberichter S. L., Balistreri M., Christopherson P., et al. Assay of the Von Willebrand factor (VWF) propeptide to identify patients with type 1 Von Willebrand disease with decreased VWF survival. Blood: 2006; 108 10 3344 3351
63. Haberichter S. L., Castaman G., Budde U., et al. Identification of type 1 Von Willebrand disease patients with reduced Von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood: 2008; 111 10 4979 4985
64. Castaman G., Lethagen S., Federici A. B., et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 Von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood: 2008; 111 7 3531 3539
65. Mancuso D. J., Tuley E. A., Westfield L. A., et al. Structure of the gene for human Von Willebrand factor. J Biol Chem: 1989; 264 33 19514 19527 (Pubitemid 20008053)
66. Goodeve A., Eikenboom J., Castaman G., et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 Von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 Von Willebrand Disease (MCMDM-1VWD). Blood: 2007; 109 1 112 121 (Pubitemid 46053051)
67. James P. D., Notley C., Hegadorn C., et al. The mutational spectrum of type 1 Von Willebrand disease: Results from a Canadian cohort study. Blood: 2007; 109 1 145 154 (Pubitemid 46053055)
68. Sutherland M. S., Cumming A. M., Bowman M., et al. A novel deletion mutation is recurrent in Von Willebrand disease types 1 and 3. Blood: 2009; 114 5 1091 1098
69. Gallinaro L., Cattini M. G., Sztukowska M., et al. A shorter Von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma Von Willebrand factor. Blood: 2008; 111 7 3540 3545
70. Rydz N., Swystun L. L., Notley C., et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears Von Willebrand factor and contributes to the variation in plasma Von Willebrand factor levels. Blood: 2013; 121 26 5228 5237
71. Bellissimo D. B., Christopherson P. A., Flood V. H., et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood: 2012; 119 9 2135 2140
72. Ruggeri Z. M., Pareti F. I., Mannucci P. M., Ciavarella N., Zimmerman T. S. Heightened interaction between platelets and factor VIII/Von Willebrand factor in a new subtype of Von Willebrand's disease. N Engl J Med: 1980; 302 19 1047 1051 (Pubitemid 10123105)
73. Scott J. P., Montgomery R. R. The rapid differentiation of type IIb Von Willebrand's disease from platelet-type (pseudo-) Von Willebrand's disease by the neutral monoclonal antibody binding assay. Am J Clin Pathol: 1991; 96 6 723 728
74. Favaloro E. J. Phenotypic identification of platelet-type Von Willebrand disease and its discrimination from type 2B Von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost: 2008; 34 1 113 127
75. Montgomery R. R., Hathaway W. E., Johnson J., Jacobson L., Muntean W. A variant of Von Willebrand's disease with abnormal expression of factor VIII procoagulant activity. Blood: 1982; 60 1 201 207 (Pubitemid 12085940)
76. Gupta M., Lillicrap D., Stain A. M., Friedman K. D., Carcao M. D. Therapeutic consequences for misdiagnosis of type 2N Von Willebrand disease. Pediatr Blood Cancer: 2011; 57 6 1081 1083
77. Lawrie A. S., Stufano F., Canciani M. T., Mackie I. J., Machin S. J., Peyvandi F. A comparative evaluation of a new automated assay for Von Willebrand factor activity. Haemophilia: 2013; 19 2 338 342
78. Verfaillie C. J., De Witte E., Devreese K. M. Validation of a new panel of automated chemiluminescence assays for Von Willebrand factor antigen and activity in the screening for Von Willebrand disease. Int J Lab Hematol: 2013; 35 5 555 565
79. Favaloro E. J., Bonar R., Chapman K., Meiring M., Funk Adcock D. Differential sensitivity of Von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost: 2012; 10 6 1043 1054
80. Favaloro E. J., Thom J., Patterson D., et al. Desmopressin therapy to assist the functional identification and characterisation of Von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) Von Willebrand factor activity assays? Thromb Res: 2009; 123 6 862 868